Update on pharmacogenetics in cancer chemotherapy.

Article Details

Citation

Innocenti F, Ratain MJ

Update on pharmacogenetics in cancer chemotherapy.

Eur J Cancer. 2002 Mar;38(5):639-44.

PubMed ID
11916544 [ View in PubMed
]
Abstract

This review describes how genetic differences among patients may change the therapeutic outcome in cancer chemotherapy. Severe toxicity in genetically predisposed patients is predominantly associated with mutations in drug metabolism enzyme genes, and an update on genetic intolerance to 6-mercaptopurine, 5-fluorouracil, and irinotecan is provided. Moreover, recent findings pointed out that the methylenetetrahydrofolate reductase (MTHFR) C677T mutation might change patient susceptibility to the toxic effects of the cyclophosphamide, methotrexate, 5-fluorouracil (CMF) regimen and raltitrexed. Finally, it is emerging that not only toxicity, but also response to chemotherapy could be influenced by pharmacogenetic determinants, and the clinical relevance of polymorphisms in thymidylate synthase (TS) and glutathione-S-transferase (GST) genes is discussed.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
RaltitrexedFolylpolyglutamate synthase, mitochondrialProteinHumans
Unknown
Antagonist
Details